Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.1 EUR | -4.98% | +5.53% | -40.93% |
May. 13 | AB Science: European patent granted for masitinib | CF |
May. 03 | AB Science: upbeat after legal success | CF |
Sales 2023 | 970K 1.05M | Sales 2024 * | 990K 1.08M | Capitalization | 107M 117M |
---|---|---|---|---|---|
Net income 2023 | -10M -10.87M | Net income 2024 * | -18M -19.56M | EV / Sales 2023 | 187 x |
Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 108 x |
P/E ratio 2023 |
-17.8
x | P/E ratio 2024 * |
-5.83
x | Employees | 89 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.05% |
Latest transcript on AB Science
1 day | -4.98% | ||
1 week | +5.53% | ||
Current month | +9.49% | ||
1 month | +5.53% | ||
3 months | -41.42% | ||
6 months | -27.34% | ||
Current year | -40.93% |
Managers | Title | Age | Since |
---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 01-07-10 |
Laurent Guy
DFI | Director of Finance/CFO | - | 01-12-31 |
Chief Tech/Sci/R&D Officer | - | 18-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 01-07-10 |
Patrick Moussy
BRD | Director/Board Member | - | 01-07-10 |
Director/Board Member | 62 | 21-06-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 2.1 | -4.98% | 188,925 |
24-05-16 | 2.21 | -3.07% | 250,796 |
24-05-15 | 2.28 | +8.57% | 299,276 |
24-05-14 | 2.1 | +3.45% | 159,668 |
24-05-13 | 2.03 | +2.01% | 71,578 |
Real-time Euronext Paris, May 17, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-40.93% | 117M | |
+16.03% | 79.03B | |
+10.23% | 8.96B | |
-10.76% | 5.19B | |
+51.58% | 4.77B | |
+12.50% | 4.26B | |
-20.70% | 2.37B | |
+12.83% | 2.3B | |
-29.65% | 2.21B | |
+19.51% | 2.17B |
- Stock Market
- Equities
- AB Stock